Clinical Roundup Perjeta biosimilar safe and effective for breast cancer in phase III trial October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Retevmo for medullary thyroid cancer with RET mutation October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Cologuard Plus Test for non-invasive CRC screening October 04, 2024Vol.50 No.37
Regulatory News ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications September 27, 2024Vol.50 No.36By Jacquelyn Cobb
PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends September 27, 2024Vol.50 No.36By Jacquelyn Cobb
Cancer History ProjectGuest Editorial How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer September 27, 2024Vol.50 No.36By Stacy Wentworth
In Brief Sanya Springfield named NCI acting deputy director for health equity and inclusion September 27, 2024Vol.50 No.36
